EuroBiotech: More Articles of Note


> Cassiopea posted more positive data on its pipeline. On Monday, the company reported interim data on clascoterone in androgenetic alopecia. Days later, Cassiopea added phase 2 genital wart data to its list of recent readouts. Release I More

> Takeda struck a deal to assess the feasibility of leon-nanodrugs’ MicroJet Reactor. Statement 

> Silence Therapeutics named David Horn Solomon as its CEO. Solomon ran Zealand Pharma from 2008 to 2015. Release

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

> Poxel posted data from a phase 1b NASH trial. The French biotech will now move the candidate into phase 2a. Statement

> Adaptimmune received clearance for dose escalation in its MAGE-A10 pilot studies. Release